NKM-1Homo sapiens (Human)Cancer cell line

Also known as: NKM1

🤖 AI SummaryBased on 4 publications

Quick Overview

Human acute myeloid leukemia cell line for cancer research.

Detailed Summary

The NKM-1 cell line is derived from a patient with acute myeloid leukemia (FAB M2) and is used in research related to hematological malignancies. It has been studied for its response to arsenic trioxide, showing effects on proliferation and apoptosis. The cell line is part of various cancer research initiatives, including studies on genetic mutations and therapeutic responses. Its characteristics include sensitivity to certain chemotherapeutic agents and potential applications in understanding leukemia biology.

Research Applications

Hematological malignancies researchApoptosis and cell cycle studiesChemotherapy response analysis

Key Characteristics

Sensitivity to arsenic trioxideUsed in leukemia studies

Generated on 6/17/2025

Basic Information

Database ID	CVCL_1607
Species	Homo sapiens (Human)
Tissue Source	Peripheral blood[UBERON:UBERON_0000178]

Donor Information

Age	33
Age Category	Adult
Sex	Male

Disease Information

Disease	Acute myeloid leukemia
Lineage	Myeloid
Subtype	Acute Myeloid Leukemia
OncoTree Code	AML

DepMap Information

Source Type	JCRB
Source ID	ACH-002290_source

Haplotype Information (STR Profile)

Short Tandem Repeat (STR) profile for cell line authentication.

Amelogenin

CSF1PO

D13S317

11,13

D16S539

9,12

D5S818

10,12

D7S820

10,11

TH01

6,9

TPOX

9,11

vWA

Gene Expression Profile

Gene expression levels and statistical distribution

Loading cohorts...

Full DepMap dataset with combined data across cell lines

Loading gene expression data...

Publications

Pan-cancer proteomic map of 949 human cell lines.";

Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.

Cancer Cell 40:835-849.e8(2022).

DOI PubMed PMC

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.

Cancer Res. 79:1263-1273(2019).

DOI PubMed PMC

A landscape of pharmacogenomic interactions in cancer.";

Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.

Cell 166:740-754(2016).

DOI PubMed PMC

Signatures of mutation and selection in the cancer genome.";

Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.

Nature 463:893-898(2010).

DOI PubMed PMC

Expression of the TCL1 gene at 14q32 in B-cell malignancies but not in adult T-cell leukemia.

Aizawa Y., Ueda R., Seto M.

Jpn. J. Cancer Res. 89:712-718(1998).

DOI PubMed PMC

The induction of apoptosis and cell cycle arrest by arsenic trioxide in lymphoid neoplasms.

Takeshita K., Takeshita A., Ohno R.

Leukemia 12:1383-1391(1998).

DOI PubMed

Up-regulation of transferrin receptor gene expression by granulocyte colony-stimulating factor in human myeloid leukemia cells.

Morishima Y., Saito H.

Cancer Res. 50:7955-7961(1990).

PubMed

A novel human myeloid leukemia cell line, NKM-1, coexpressing granulocyte colony-stimulating factor receptors and macrophage colony-stimulating factor receptors.

Kato Y., Inoue H., Saito H.

Cancer Res. 50:7703-7709(1990).

PubMed

Enhanced expression of DNA topoisomerase II by recombinant human granulocyte colony-stimulating factor in human leukemia cells.

Morishima Y., Andoh T., Saito H.

Cancer Res. 50:7198-7202(1990).

PubMed

The leukemia-lymphoma cell line factsbook.";

Drexler H.G.

(In book) ISBN 9780122219702; pp.1-733; Academic Press; London; United Kingdom (2001).

DOI